Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice
暂无分享,去创建一个
[1] I. Cuthill,et al. Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .
[2] Mardas Daneshian,et al. Critical evaluation of the use of dogs in biomedical research and testing in Europe. , 2011, ALTEX.
[3] Gian Paolo Rossini,et al. Towards tailored assays for cell-based approaches to toxicity testing. , 2012, ALTEX.
[4] Thomas Hartung,et al. The dawning of a new age of toxicology. , 2008, ALTEX.
[5] David J Gladstone,et al. Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions , 2002, Stroke.
[6] R. Matthews,et al. Medical progress depends on animal models - doesn't it? , 2008, Journal of the Royal Society of Medicine.
[7] P. Sandercock,et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2007, BMJ : British Medical Journal.
[8] P Smith,et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.
[9] Mardas Daneshian,et al. Validation and quality control of replacement alternatives - Current status and future challenges , 2012 .
[10] Thomas Hartung,et al. Food for thought... on animal tests. , 2008, ALTEX.
[11] G. Donnan,et al. 1,026 Experimental treatments in acute stroke , 2006, Annals of neurology.
[12] Malcolm Macleod,et al. Animal models of neurological disease: are there any babies in the bathwater? , 2010, Practical Neurology.
[13] M. Leist,et al. Food for thought... on the real success of 3R approaches. , 2008, ALTEX.
[14] R. Gamelli,et al. Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013, Proceedings of the National Academy of Sciences.
[15] Thomas Hartung,et al. Food for Thought ... on mapping the human toxome. , 2011, ALTEX.
[16] D. Redelmeier,et al. Translation of research evidence from animals to humans. , 2006, JAMA.
[17] Susan Green,et al. Medical progress depends on animal models – doesn't it? , 2008, Journal of the Royal Society of Medicine.
[18] Thomas Hartung,et al. Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. , 2012, ALTEX.
[19] D. Howells,et al. Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy , 2010, PLoS biology.
[20] Dwaine F. Emerich. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? , 1999 .
[21] Panagiota Anyfanti,et al. Immunomodulatory therapy for sepsis: an update , 2011, Expert review of anti-infective therapy.
[22] D. Housman,et al. Ouabain resistance conferred by expression of the cDNA for a murine Na+, K+-ATPase alpha subunit. , 1987, Science.
[23] Raccoon and Dog. The best laid plans of mice and men , 2014, SOEN.
[24] T. Hartung. Toxicology for the twenty-first century , 2009, Nature.
[25] A. Schnerch,et al. Distinguishing Between Mouse and Human Pluripotent Stem Cell Regulation: The Best Laid Plans of Mice and Men , 2010, Stem cells.
[26] D. Rittirsch,et al. The disconnect between animal models of sepsis and human sepsis , 2007, Journal of leukocyte biology.
[27] Thomas Vogl,et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel , 2010, Nature Immunology.
[28] Thomas B Knudsen,et al. Systems Toxicology , 2015, International journal of toxicology.
[29] M. Youdim,et al. The Future of Neuroprotection , 1999, Annals of the New York Academy of Sciences.
[30] Marcel Leist,et al. Food for thought ... considerations and guidelines for basic test method descriptions in toxicology. , 2010, ALTEX.
[31] Douglas G. Altman,et al. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research , 2010, Journal of pharmacology & pharmacotherapeutics.
[32] Chihae Yang,et al. Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods. , 2012, ALTEX.
[33] M. Macleod,et al. Preclinical studies of human disease: time to take methodological quality seriously. , 2011, Journal of molecular and cellular cardiology.
[34] L. Gold,et al. Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.
[35] P. Lane,et al. A broader view of animal research , 2007, BMJ : British Medical Journal.
[36] Ulrich Dirnagl,et al. International, Multicenter Randomized Preclinical Trials in Translational Stroke Research: It's Time to Act , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[37] D. Howells,et al. Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.
[38] Thomas Hartung,et al. Food for thought ... on the evolution of toxicology and the phasing out of animal testing. , 2008, ALTEX.
[39] Thomas Hartung,et al. Food for thought ... on alternative methods for cosmetics safety testing. , 2008, ALTEX.
[40] M. Wadhwa,et al. “Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics , 2007, The Journal of Immunology.
[41] M. Fisher,et al. Future of neuroprotection for acute stroke: In the aftermath of the SAINT trials , 2007, Annals of neurology.
[42] P. Sandercock,et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.
[43] T. Miyakawa,et al. Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013 .
[44] Amy Ellis,et al. Critical evaluation of the use of dogs in biomedical research and testing , 2011 .
[45] M. Sitkovsky,et al. Model organisms: Animal Models of sepsis: setting the stage , 2005, Nature Reviews Drug Discovery.
[46] Bas J Blaauboer,et al. The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. , 2012, ALTEX.
[47] Mardas Daneshian,et al. Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test. , 2013, ALTEX.
[48] A. Pérez-Bouza,et al. Neurally Mediated Airway Constriction in Human and Other Species: A Comparative Study Using Precision-Cut Lung Slices (PCLS) , 2012, PloS one.
[49] J. Keyser,et al. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? , 1999, Trends in Neurosciences.
[50] S. Opal,et al. Clinical trials for severe sepsis. Past failures, and future hopes. , 1999, Infectious disease clinics of North America.
[51] U. Dirnagl,et al. REPRINT: International, multicenter randomized preclinical trials in translational stroke research: it is time to act. , 2012, Stroke.
[52] T. Knudsen,et al. A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing. , 2012, ALTEX.
[53] D. Blacker. Food for thought. , 2013, JAMA neurology.